Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 77Leukemia 74Leukemia, Lymphocytic, Chronic, B-Cell 68Myelodysplastic Syndromes 56Lymphoma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 45Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38Hodgkin Disease 36Melanoma 25Hematologic Neoplasms 25Recurrence 19Neoplasms 17Myeloproliferative Disorders 17Neoplasm Metastasis 15Lymphoma, Follicular 15Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Mantle-Cell 13Skin Neoplasms 11Graft vs Host Disease 11Burkitt Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Leukemia, Myelomonocytic, Chronic 9Hematologic Diseases 8Breast Neoplasms 8

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × fludarabine × Clear all
NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡